Stockscreener 앱 받기
0.6021
1.30%
-0.0079
Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스
ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com
ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com
Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus
Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq
ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire
Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia
Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia
ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com Australia
ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian
ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - TradingView
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa
ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks
ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India
0.39%
3.66%
자본화:
|
볼륨(24시간):